alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
                                                                    EXHIBIT 99.1

      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                                   PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



I, Jimmy S.M. Lee, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Integrated Silicon Solution, Inc. on Form 10-Q for the quarterly
period ended March 31, 2003 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Report on Form 10Q fairly presents in all material respects
the financial condition and results of operations of Integrated Silicon Solution
Inc.



                       By: /s/ Jimmy S.M. Lee
                          -------------------


                          Jimmy S.M. Lee
                          Chairman of the Board and Chief Executive Officer
                          May 15, 2003



I, Gary L. Fischer, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly
Report of Integrated Silicon Solution, Inc. on Form 10-Q for the quarterly
period ended March 31, 2003 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934 and that information
contained in such Report on Form 10Q fairly presents in all material respects
the financial condition and results of operations of Integrated Silicon Solution
Inc.



                       By: /s/ Gary L. Fischer
                          -------------------


                           Gary L. Fischer
                           President, Chief Operating Officer and
                           Chief Financial Officer
                           May 15, 2003
Preston Lee JOHNSON, Jr., petitioner, v. UNITED STATES.

No. 17-9308.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Christopher PAIGE, et ux., petitioners, v. LERNER MASTER FUND, LLC, et al.

No. 18-1178.

Supreme Court of the United States

May 13, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
**THE SUPREME COURT OF TEXAS**

**Post Office Box 12248**

**Austin, Texas 78711**

**(512) 463-1312**

April 03, 2009

Mr. Mike A. Hatchell

Locke Lord Bissell & Liddell, LLP

100 Congress Avenue, Suite 300

Austin, TX 78701-4042

Mr. Bruce S. Powers

Assistant County Attorney

1019 Congress, 15th Floor

Houston, TX 77002

RE:Case Number:  06-0933

Court of Appeals Number:  01-05-00668-CV

Trial Court Number:  807,506

Style:SOUTHWESTERN BELL TELEPHONE, L.P., D/B/A SBC TEXAS

v.

HARRIS COUNTY TOLL ROAD AUTHORITY AND HARRIS COUNTY

Dear Counsel:

Today the Supreme Court of Texas delivered the enclosed opinion and judgment in the above-referenced cause.  

Sincerely,

Blake A. Hawthorne, Clerk

by Claudia Jenks, Chief Deputy Clerk

Enclosures

**Case No. 06-0933Page 1**
Billy R. MELOT, petitioner, v. COMMISSIONER OF INTERNAL REVENUE.

No. 18-5076.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
Tommy NELSON, Jr., petitioner, v. UNITED STATES.

No. 18-8601.

Supreme Court of the United States

April 29, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
KANSAS, petitioner, v. Charles GLOVER.

No. 18-556.

Supreme Court of the United States

May 28, 2019.

Motion of petitioner to dispense with printing the joint appendix granted.
```

[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29356]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10355]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed 
Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Heart, Lung, and Blood Institute 
Special Emphasis Panel; Research Education Program to Enhance 
Diversity in Health Related Research.
    Date: June 24, 2022.
    Time: 9:00 a.m. to 1:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6705 Rockledge Drive, 
Bethesda, MD 20817 (Virtual Meeting).
    Contact Person: Shelley Sehnert, Ph.D., Scientific Review 
Officer, Office of Scientific Review/DERA, National Heart, Lung, and 
Blood Institute, National Institutes of Health, 6705 Rockledge 
Drive, Suite 208-T, Bethesda, MD 20817, (301) 827-7984, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, 
National Center for Sleep Disorders Research; 93.837, Heart and 
Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, 
Blood Diseases and Resources Research, National Institutes of 
Health, HHS)

    Dated: May 10, 2022.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-10355 Filed 5-12-22; 8:45 am]
BILLING CODE 4140-01-P
```
```
  
 
WHEAT - KANSAS CITY BOARD OF TRADE                                   Code-001612
OPTION AND FUTURES COMBINED POSITIONS AS OF 02/01/11          |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  Long  | Short  |Spreads |  Long  | Short  |  Long  | Short  |  Long  | Short
--------------------------------------------------------------------------------
(CONTRACTS OF 5,000 BUSHELS)                         OPEN INTEREST:      228,776
COMMITMENTS
  68,275    5,788   37,189   87,582  153,951  193,045  196,928   35,730   31,848

CHANGES FROM 01/25/11 (CHANGE IN OPEN INTEREST:      3,920)
     180   -1,089    1,927      899    3,808    3,006    4,645      914     -725

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADER
    29.8      2.5     16.3     38.3     67.3     84.4     86.1     15.6     13.9

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      220)
      77       25       61       69       94      169      164
```

----

Updated February 4, 2011
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM
FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED SEPTEMBER 30, 1999 AND IS
QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             APR-01-1999
<PERIOD-END>                               SEP-30-1999
<CASH>                                          12,024
<SECURITIES>                                    18,682
<RECEIVABLES>                                   31,519
<ALLOWANCES>                                   (1,905)
<INVENTORY>                                     23,789
<CURRENT-ASSETS>                               106,996
<PP&E>                                          35,292
<DEPRECIATION>                                (21,730)
<TOTAL-ASSETS>                                 139,084
<CURRENT-LIABILITIES>                           26,410
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       135,716
<OTHER-SE>                                    (23,042)
<TOTAL-LIABILITY-AND-EQUITY>                   139,084
<SALES>                                         67,782
<TOTAL-REVENUES>                                67,782
<CGS>                                           38,167
<TOTAL-COSTS>                                   36,376
<OTHER-EXPENSES>                                 (285)
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 143
<INCOME-PRETAX>                                (6,476)
<INCOME-TAX>                                     (842)
<INCOME-CONTINUING>                            (5,634)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,634)
<EPS-BASIC>                                     (0.45)
<EPS-DILUTED>                                   (0.45)


</TABLE>
**Exhibit 32**

**CERTIFICATIONS PURSUANT TO 18 U.S.C. SECTION 1350**

In connection with the Quarterly Report ofTitan Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Louis R. Bucalo, M.D.,Chairman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company for the periodcertified. 

Signed at the City of South San Francisco, in the State of California,this 9th day of May, 2007. 

 

In connection with the Quarterly Report of Titan Pharmaceuticals, Inc. (the“Company”) on Form 10-Q for the period ended March 31, 2007 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert E. Farrell, J.D., Executive Vice President and ChiefFinancial Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company for theperiod certified. 

Signed at the City of South San Francisco, in the State ofCalifornia, this 9th day of May, 2007.
----

|        |        |        |                                                                                                                                                                                                                                                      |
|--------|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (1     | )      |   | the Annual Report on Form 10-K of the Company for the annual period ended December 31, 2010 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and |
|   |   |   |
| (2     | )      |   | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.                                                                                                 |

|                         |                                                                       |        |
|-------------------------|-----------------------------------------------------------------------|--------|
| Date: February 28, 2011 | /s/ Patrick J. Goodman                                                |   |
|                    | Patrick J. Goodman                                                    |   |
|                    | Senior Vice President and Chief Financial Officer |   |
|                    | (principal financial officer)                                         |   |

----
Monty M. SHELTON, petitioner, v. Gene BEASLEY, Warden.

No. 18-8182.

Supreme Court of the United States

April 15, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.

Justice KAGAN took no part in the consideration or decision of this petition.
Exhibit 99.3

**CERTIFICATION**

I, Paul E.Blevins., Chief Financial Officer for Onsite Energy Corporation, a Delaware corporation (the “Registrant”), certify that:

1.          Ihave reviewed this quarterly report on Form 10-QSB of  the Registrant for the period ending September 30, 2002;

2.          Based on myknowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleadingwith respect to the period covered by this quarterly report; 

3.          Based on my knowledge, the consolidated financial statements, and otherfinancial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this quarterly report;

4.          The Registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls andprocedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Registrant and we have:

             a)          designed such disclosure controls and procedures to ensure that material informationrelating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;

             b)          evaluated the effectiveness of the Registrant’s disclosure controls andprocedures as of a date within 90 days prior to the filing date of this quarterly report (the “Evaluation Date”); and

             c)          presented in this quarterly report our conclusions about the effectiveness of thedisclosure controls and procedures based on our evaluation as of the Evaluation Date;

5.          The Registrant’s other certifying officers andI have disclosed, based on our most recent evaluation, to the Registrant’s auditors and the Audit Committee of Registrant’s Board of Directors (or persons performing the equivalent function):

             a)          all significant deficiencies in the design or operation of internal controls whichcould adversely affect the Registrant’s ability to record, process, summarize and report financial data and have identified for the Registrant’s auditors any material weaknesses in internal controls; and

             b)          any fraud, whether or not material, that involves management or other employees whohave a significant role in the Registrant’s internal controls; and

6.          The Registrant’s other certifying officers and I haveindicated in this quarterly report whether or not there were significant changes in internal controls or in other factors that could significantly affect
Vincent Allen KNAPP, petitioner, v. UNITED STATES.

No. 17-9511.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Pages 29379-29380]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10266]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Pistoia Alliance, Inc.

    Notice is hereby given that, on March 31, 2022, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Pistoia Alliance, Inc. filed 
written notifications simultaneously with the Attorney General and the 
Federal Trade Commission disclosing changes in its membership. The 
notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, Vertex Inc., 
Boston, MA; Nagarro, Cluj-Napoca, ROMANIA; Exscientia, Oxford, UNITED 
KINGDOM; Atom Computing, Berkeley, CA; The Lens, Karabar, AUSTRALIA; 
IonQ Inc., College Park, MD; Prism Analytic, Cambridge, MA; and 
Accurids GmbH, Aachen, GERMANY have been added as parties to this 
venture.
    Also, World Quant Predictive, New York, NY; Scinapsis, Toronto, 
CANADA; Synthace, London, UNITED KINGDOM; Qiagen, Redwood City, CA; 
Illumina, San Diego, CA; Mcule, Budapest, HUNGARY; Sapio, Baltimore, 
MD; PercayAI, St. Louis, MO; Titian, London, UNITED KINGDOM; Tellic, 
New York, NY; and GenAlz, Montreal, CANADA have withdrawn as parties to 
this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Pistoia Alliance, Inc. intends to 
file additional written notifications disclosing all changes in 
membership.
    On May 28, 2009, Pistoia Alliance, Inc. filed its original 
notification pursuant to Section 6(a) of the Act. The Department of 
Justice published a notice

[[Page 29380]]

in the Federal Register pursuant to Section 6(b) of the Act on July 15, 
2009 (74 FR 34364).
    The last notification was filed with the Department on December 8, 
2021. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act was published on March 11, 2022 (87 FR 14043).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10266 Filed 5-12-22; 8:45 am]
BILLING CODE 4410-11-P
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29384]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10274]



[[Page 29384]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--R Consortium, Inc.

    Notice is hereby given that, on April 23, 2022, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), R Consortium, Inc. (``R 
Consortium'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances. 
Specifically, Pfizer, Collegeville, PA, has been added as a party to 
this venture.
    Also, Alteryx Inc., Irvine, CA, has withdrawn as a party to this 
venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and R Consortium intends to file 
additional written notifications disclosing all changes in membership.
    On September 15, 2015, R Consortium filed its original notification 
pursuant to Section 6(a) of the Act. The Department of Justice 
published a notice in the Federal Register pursuant to Section 6(b) of 
the Act on October 2, 2015 (80 FR 59815).
    The last notification was filed with the Department on February 2, 
2022. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on March 11, 2022 (87 FR 14045).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10274 Filed 5-12-22; 8:45 am]
BILLING CODE
Mark STUART, petitioner, v. Jim LANE, et al.

No. 18-975.

Supreme Court of the United States

April 1, 2019.

Petition for writ of certiorari to the Court of Appeals of Arizona, Division One denied.
E. DRAKE, petitioner, v. MURPHY, AUSTIN, ADAMS, SCHOENFELD, et al.

No. 18-8515.

Supreme Court of the United States

May 28, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Fifth Circuit denied.
NEXTERA ENERGY, INC., petitioner, v. ELLIOTT ASSOCIATES, L.P., et al.

No. 18-957.

Supreme Court of the United States

April 29, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Third Circuit denied.
Jose SOLIS, petitioner, v. UNITED STATES.

No. 17-9543.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the United States Court of Appeals for the Eleventh Circuit denied.
Teresa BIERMAN, et al., petitioners, v. Tim WALZ, Governor of Minnesota, et al.

No. 18-766.

Supreme Court of the United States

May 13, 2019.

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002

In connection with the annual
report of China TransInfo Technology Corp. (the Company) on Form 10-K/A for
the period ended December 31, 2008 as filed with the Securities and Exchange
Commission on the date hereof (the Report), I, Shudong Xia, Chief Executive
Officer and President of the Company, certify, pursuant to 18 U.S.C. § 1350, as
adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934; and

(2) The information contained in
the Report fairly presents, in all material respects, the financial condition
and result of operations of the Company.

| | /s/
      Shudong Xia                    
| | -----------------------------------------
| | Shudong Xia                              
| | President & Chief Executive
      Officer

December 28, 2009

A signed original of this written statement required by Section
906 has been provided to China TransInfo Technology Corp. and will be retained
by China TransInfo Technology Corp. and furnished to the Securities and Exchange
Commission or its staff upon request.

The forgoing certification is being furnished to the Securities
and Exchange Commission pursuant to § 18 U.S.C. Section 1350. It is not being
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, and is not to be incorporated by reference into any filing of the
Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.

---